Company: STAA
Filing Date: 2025-09-24
Form Type: DFAN14A
Source: 0001213900-25-091197
Chunk: 26

Company: STAAR SURGICAL CO
Filing Date: 2025-09-24
Form: DFAN14A
Chunk 26
---
 TO VOTE AGAINST RESOURCES HOW TO VOTE CONTACT

Exhibit 3

<div align='center'>Yunqi Capital, 5.1% Holder and One of STAAR
Surgical Company’s Largest Shareholders, Announces Intention to Vote Against the Proposed Sale to Alcon

Issues Open Letter to Shareholders Outlining Its Belief that the Proposed Merger Materially Undervalues STAAR

Contends that STAAR’s Board Failed In Its Responsibilities by Not Running a Thorough Process and Relying on Undue Skepticism about the Company’s Prospects

Shareholders Deserve Fair Value for the Company</div>

HONG KONG, September 22, 2025 – Yunqi Capital Limited (together
with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR
Surgical Company (“STAAR”) (NASDAQ:STAA), today announced its opposition to the Company’s proposed sale to Alcon Inc.
(SIX/NYSE:ALC) on the terms announced on August 5, 2025.

Yunqi Capital released the following open letter to fellow STAAR shareholders
explaining why it opposes the transaction:

September 22, 2025

Dear Fellow STAAR Surgical Shareholders:

Yunqi Capital Limited (together with its affiliates, “Yunqi Capital”
or “we”) is an investment management firm that has been a committed investor in, and staunch advocate of, STAAR Surgical Company
(“STAA” or the “Company”) since 2023. We have engaged consistently with the Company since the outset of our investment,
in particular with respect to the Company’s strong business prospects in the Chinese market which accounts for a significant portion
of the Company’s sales. Our investment in STAAR has grown over time, consistent with our belief in the Company’s growth strategy,
management team and market opportunities. Today, we beneficially own 2,500,061 shares of STAAR’s common stock, representing approximately
5.1% of the Company, making us the Company’s approximately sixth largest shareholder.

We invested in STAAR because we believe strongly in the Company’s
ability to create substantial value as the leading manufacturer of phakic implantable lenses used worldwide in corrective (or “refractive”)
surgery. We are confident in the Company’s ability to drive sustained growth as it positions its refractive lenses throughout the
world as